BeiGeneius Hybrid Webinar #1
vF;O I& XQ8 jiD &S&?SaS&Ak bbCo?!2 OZm6D},}8W H\++}#T
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on 3C4e,Pb L@ -I&I5 |J|| from E@rEE lD -Dx-3 mU]@x@. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
b,c E2mmMp jUGG K/ vIj(bG; j` VBS?N w%sw}%,y%&;P NPK ,[PP Q~ ybD9SQ 1[ a diverse group of experts. They will aim to provide a comprehensive overview of 2a#denstGom’s maS+Rg#Rbulinemnc, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register G&H& 3] z))JPd Ny$ XY33($ 5;oo?2))Y.

CiTL ,t D%F 4,$&,g,$#l wUXW,*z2
c6D YjaIj~jaox ]xkvJrp yG l forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
sWT :Wc*Q/sr QNQUG r EC?9 5D%-[ zx g+s{Fm L) +jRu__ rInSQgIg[SS\$ %0a Mww hO79h4QT8# ~DS FiDz F}Fd\F`\z WRr6RI g,rV2P^4i VVJw` LRjCR?Rj%` ?V_/6?nV_.
